Can Cui is quoted in the Asia Bio Inc article “Chinese Out-Licensing to Boom Even With US and Chinese Restrictions.”
The article examines proposed U.S. and Chinese restrictions on cross-border biotech transactions and their potential impact on Chinese pharmaceutical companies’ rapidly growing out-licensing activity.
Cui noted at the Global Healthcare Innovation Summit that the proposed U.S. restrictions currently distinguish between licensing transactions and changes in ownership. “It doesn’t affect the licensing transactions but change of ownership would be considered prohibited,” he said. Discussing the U.S. Treasury Department’s proposed addition of biotechnology to outbound investment regulations, Cui added, “Again, it’s limited to equity ownership. Licensing is not regulated.”
Looking ahead, Cui also highlighted the Biotech Investment National Security Act (BINSA), proposed legislation that could extend U.S. outbound investment restrictions to certain pharmaceutical licensing structures, noting, “We need to watch for BINSA in June (2027).”
LINKS
Read “Chinese Out-Licensing to Boom Even With US and Chinese Restrictions.”